Naslov
Methotrexate for Cardiovascular Risk Reduction: The Right Choice?

Autori
Reiner, Željko ; Sirtori, Cesare R. ; Banach, Maciej ; Ruscica, Massimiliano ; Sahebkar, Amirhossein

Izvornik
Angiology (0003-3197) 71 (2019), 2; 105-107

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, uvodnik, znanstveni

Ključne riječi
methotrexate ; cardiovascular risk

Sažetak
The causative role of inflammation in atherosclerosis and cardiovascular (CV) disease (CVD) has been well established.1 Rheumatoid arthritis (RA), a condition associated with systemic inflammation, is included in the CVD risk calculation provided by an analysis of the national QRESEARCH database that included 2.3 million people.2 Furthermore, in clinical practice, the most recent European guidelines clearly state that RA enhances CVD risk independent of traditional risk factors, with a risk ratio of 1.4 and 1.5 for men and women, respectively.3 Thus, there is now considerable evidence supporting that CVD incidence is increased by about 50% in patients with RA and that one of the leading causes of increased mortality in these patients is early CVD caused by accelerated atherogenesis.4 Therefore, the Cardiovascular Inflammation Reduction Trial (CIRT) trial aimed to assess the effect of inhibiting inflammation with low-dose methotrexate (vs placebo) on the rate of CV events in coronary patients with either type 2 diabetes or metabolic syndrome

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA